Wang Xiaoyi, Wang Ying, Feng Xiaoyuan, Lu Ying, Zhang Yu, Wang Wenwen, Zhu Wentao
School of Management, Beijing University of Chinese Medicine, Beijing, People's Republic of China.
Drug Des Devel Ther. 2016 Nov 14;10:3725-3736. doi: 10.2147/DDDT.S112333. eCollection 2016.
The aim of the study was to evaluate the effectiveness, safety, and cost associated with Wenxin keli in the treatment of cardiovascular diseases based on meta-analysis.
The terms "Wenxin keli" and "Wenxin" were used as the search terms in the PubMed, ProQuest, Springer, the Cochrane Library, CNKI (China National Knowledge Infrastructure), VIP (Chinese Scientific Journals Database), and Wan fang electronic databases (from January 2000 to October 2015). Relevant print journals and conference papers were also searched. Studies on randomized controlled trials (RCTs) of Wenxin keli used in the treatment of cardiovascular diseases were screened, and its indications were classified. Meta-analysis of these studies was conducted using the RevMan 5.2 software.
A total of 49 RCTs (n=4,610) were included, 29 of which focused on arrhythmia, seven on angina, seven on heart failure, two on viral myocarditis, and four on menopausal syndrome. Analysis of the therapeutic indications of Wenxin keli showed that it was comparatively more curative and effective than other available treatments for cardiovascular diseases.
Wenxin keli showed better clinical efficacy in the treatment of arrhythmia, angina, and heart failure; however, more high-quality evidence is needed to support its use in the clinical setting.
本研究旨在基于荟萃分析评估稳心颗粒治疗心血管疾病的有效性、安全性及成本。
以“稳心颗粒”和“稳心”为检索词,检索PubMed、ProQuest、Springer、Cochrane图书馆、中国知网(CNKI)、维普中文科技期刊数据库和万方电子数据库(检索时间为2000年1月至2015年10月)。同时检索相关印刷版期刊和会议论文。筛选稳心颗粒治疗心血管疾病的随机对照试验(RCT)研究,并对其适应证进行分类。使用RevMan 5.2软件对这些研究进行荟萃分析。
共纳入49项RCT(n = 4610),其中29项聚焦于心律失常,7项聚焦于心绞痛,7项聚焦于心力衰竭,2项聚焦于病毒性心肌炎,4项聚焦于更年期综合征。稳心颗粒治疗适应证分析表明,与其他现有心血管疾病治疗方法相比,其疗效相对更好。
稳心颗粒在治疗心律失常、心绞痛和心力衰竭方面显示出较好的临床疗效;然而,需要更多高质量证据支持其在临床中的应用。